Pharmasset (VRUS +6.4%) shares rise on renewed hopes for a hepatitis C drug after announcing a...

|By:, SA News Editor

Pharmasset (VRUS +6.4%) shares rise on renewed hopes for a hepatitis C drug after announcing a collaboration with Johnson & Johnson (JNJ -0.2%) to test their drugs together in a mid-stage human trial. Shares of competitor Vertex (VRTX -3.4%) slip, but have surged 40%-plus this year; also, Canaccord initiates coverage with a tepid Hold.